Samsung Biologics and Biogen Idec announced their joint venture in December and now they’ve established it under the name of Samsung Bioepis Co. Ltd. Samsung Bioepis will be responsible to develop and market biosimilars.
The venture’s R&D center will be located in Song-do Incheon, South Korea, which will help Samsung to to specialize in biopharmaceutical manufacturing.
Christopher Hansung Ko, ex-Senior Vice President of Samsung Strategic Business Development has been named the CEO of Samsung Bioepis.
wow..amazing